Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(75%)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_1
1
25%
Ph phase_2
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 22 (50.0%)

Trials by Status

terminated375%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568
terminatedearly_phase_1

PET Imaging of Subjects Using 124I-PU-AD

NCT03371420
withdrawnphase_2

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

NCT04505358
terminatedphase_2

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515

Clinical Trials (4)

Showing 4 of 4 trials
NCT03935568Phase 1

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

Terminated
NCT03371420Early Phase 1

PET Imaging of Subjects Using 124I-PU-AD

Terminated
NCT04505358Phase 2

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

Withdrawn
NCT04311515Phase 2

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4